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in clinical practice (5). SIR has also produced gui-
delines for the use of anti-TNFα agents: a diagno-
sis of RA (American College of Rheumatology
[ACR] criteria); failure to respond to at least one
course of combination therapy with full-dose tra-
ditional DMARDs, one of which should always be
methotrexate (MTX) unless contraindicated; and
active disease as defined by a 28-joint Disease Ac-
tivity Score (DAS28) of >3.7 (5). 
Active infection, a history of malignancy or pre-
malignant condition, class III/IV congestive heart
failure, and demyelinating disorders are absolute
exclusion criteria. There was initially no specific
indication for tubercular infection but, as soon as
the role of anti-TNFα agents in reactivating latent
tuberculosis (TB) became clear, the patients had to
be screened for the presence of past or latent TB
(history, Mantoux test, chest radiography). TB-po-
sitive patients could be treated with infliximab on-
ly after at least three weeks of anti-TB therapy,
INTRODUCTION
Clinical trials have shown that anti-tumour necro-sis factor (TNF)-α drugs are effective in patients
with rheumatoid arthritis (RA) refractory to disea-
se-modifying antirheumatic drugs (DMARDs) (1-4).
At about the same time as the European approval
of the third anti-TNFα agent (adalimumab) for
treating RA patients, the Italian Society of Rheu-
matology (Società Italiana di Reumatologia [SIR])
started a database for the registration and active
follow-up of RA patients treated with biological re-
sponse modifiers, which contains all of the demo-
graphic and clinical parameters, as well as the the-
rapeutic data, usually needed to follow RA patients
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SOMMARIO
L’artrite reumatoide (AR) è una patologia ad andamento cronico, caratterizzata da sinovite persistente, progressiva distruzione
delle strutture articolari e disabilità. Gli agenti biologici anti-Tumor Necrosis Factor-α (TNF-α) (etanercept, infliximab e
adalimumab) sono dotati di attività anti-infiammatoria, mediata dalla neutralizzazione del TNF-α, e presentano alcuni im-
portanti vantaggi rispetto ai “Disease-Modifying Anti-rheumatic Drugs” DMARDs. Gli agenti-anti-TNF-α sia in monoter-
apia sia in associazione al methotrexate (MTX), agiscono più rapidamente rispetto ai DMARDs e sono in grado di ridurre
l’attività di malattia non solo nei pazienti che hanno una risposta parziale ai farmaci di fondo, ma anche in quelli non respon-
sivi. Nello stesso momento in cui in Europa veniva approvato il terzo farmaco anti-TNF per trattare i pazienti affetti da ar-
trite reumatoide (AR), la Società Italiana di Reumatologia (SIR) avviava un database per registrare e monitorare i pazienti
affetti da AR trattati con i farmaci anti-TNF. Fin dal 1999, tutti i pazienti affetti da AR secondo i criteri dell’American Col-
lege of Rheumatology (ACR) trattati con almeno una dose di farmaco anti-TNF presso quattro Centri di Reumatologia siti in
Lombardia (nord est Italia) sono stati inclusi nel registro Lombardy Rheumatology Network (LORHEN) per valutare l’effi-
cacia e la sicurezza dei tre agenti anti-TNF attualmente in commercio durante i primi tre anni di trattamento.
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Table I - Baseline demographic and clinical characteristic of the 1114 RA patients included in the LORHEN Register.
Etanercept Adalimumab Infliximab Overall
Patients, n (%) 249 (22.4) 332 (29.8) 533 (47.8) 1114 (100)
Mean age, years (SD) 55.82 (14.55) 56.11 (13.01) 55.74 (12.08) 55.87 (12.93)
Females, n (%) 210 (84.3) 283 (85.2) 430 (80.7) 923 (82.9)
Males, n (%) 39 (15.7) 49 (14.8) 103 (19.3) 191 (17.1)
Mean disease duration,
years (SD) 9.61 (7.17) 9.47 (7.89) 9.22 (6.97) 9.38 (7.29)
Comorbidity, n (%) 82 (32.9) 132 (39.8) 209 (39.2) 423 (38.0)
Functional disability, n (%)
I 2 (0.8) 24 (7.2) 13 (2.4) 39 (3.5)
II 176 (70.7) 241 (72.6) 327 (61.4) 744 (66.8)
III 60 (24.1) 63 (19.0) 158 (29.6) 281 (25.2)
IV 11 (4.4) 4 (1.2) 35 (6.6) 50 (4.5)
Tuberculosis prophylaxis, 
n (%) 48 (19.3) 49 (14.8) 51 (9.6) 148 (13.3)
Mean number of
previous DMARDs (SD) 2.99 (1.24) 3.00 (1.16) 3.10 (1.22) 3.04 (1.21)
Concurrent 
corticosteroids, n (%) 210 (84.3) 254 (76.5) 471 (88.4) 935 (83.9)
Concurrent NSAIDs, n (%) 71 (28.5) 89 (26.8) 121 (22.7) 281 (25.2)
Concurrent MTX, n (%) 177 (71.1) 245 (73.8) 512 (96.1) 934 (83.8)
Other concurrent 
DMARDs, n (%) 16 (6.4) 17 (5.1) 10 (1.9) 43 (3.9)
RF positive, n (%) 185 (77.4) 236 (72.6) 427 (82.9) 848 (78.6)
Mean anti-CCP (SD) 79.23 (78.82) 93.12 (184.59) 65.86 (49.09) 79.07 (121.43)
Mean 28 SJC (SD) 10.83 (5.82) 9.64 (5.07) 9.88 (5.12) 10.02 (5.28)
Mean 28 TJC (SD) 11.38 (6.79) 10.30 (6.11) 11.87 (6.31) 11.29 (6.39)
Mean ESR, mm/h (SD) 41.66 (20.07) 36.71 (20.99) 41.32 (22.38) 40.02 (21.56)
Mean CRP, mg/dl (SD) 10.47 (9.55) 9.73 (9.68) 10.32 (9.77) 10.18 (9.69)
Mean patient global 
assessment (S.D.) 64.98 (14.26) 62.61 (14.68) 58.47 (20.15) 60.54 (18.12)
Mean DAS 28 (SD) 5.92 (1.02) 5.65 (0.96) 6.01 (0.94) 5.88 (0.97)
Mean PAIN, VAS (SD) 75.21 (14.36) 70.42 (19.52) 79.95 (12.31) 75.51 (16.04)
Mean HAQ score (SD) 1.41 (0.63) 1.25 (0.55) 1.60 (0.61) 1.45 (0.61)
Abbreviations: DMARDs = disease-modifying antirheumatic drug; NSAIDS = non-steroidal anti-inflammatory drug;
MTX = methotrexate; anti-CCP = anti-cyclic Citrullinated Peptide Antibodies; RF = rheumatoid factor;
SJC = swollen joint count; TJC = tender joint count; ESR= erythrocyte sedimentation rate; CRP = C-creative protein;
DAS28 = disease activity score 28; VAS = visual analogue scale; HAQ = health assessment questionnaire.
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which had to be continued for at least nine months.
The guidelines also included a recommendation
that rheumatologists should register all treated pa-
tients in a national register in order to study long
term safety.
Since 1999, all of the patients with RA diagnosed
on the basis of the ACR criteria (6) and treated with
at least one dose of an anti-TNF agent have been
recorded in a database shared by four Rheumatol-
ogy Centres in Lombardy (northern Italy): the
Lombardy Rheumatology Network (LORHEN)
registry.
THE LORHEN REGISTRY
This registry describes the efficacy and safety of the
first three years of treatment in a large cohort of pa-
tients with RA treated with the three currently
available TNF inhibitors: etanercept, infliximab
and adalimumab (ETA, INF, ADA).
Baseline
All of the patients with rheumatic disease who start
therapy with a biological agent are asked to give
their consent to being entered in the registry, after
which the consultant completes a standard baseline
form including demographic data, the 1987 ACR
criteria for RA (6), the individual components of
the DAS28 (7), details of all previous and current
DMARD therapy, and comorbidities; the registry
does not collect radiological data. The are also
asked to provide additional data concerning their
smoking habits and occupational history, and to
complete the Italian version of the Disability Index
of the Health Assessment Questionnaire (HAQ) (8)
and the Medical Outcome Survey Short Form 36
(SF-36) assessing the quality of life (9).
Assessments
At baseline, and after six and 12 months of follow-
up, the treating rheumatologist records each pa-
tient’s tender and swollen joint counts (28 joints),
the patient’s assessment of pain on a 100 mm vi-
sual analogue scale (VAS), the patient’s overall as-
sessment of general health on a 100 mm VAS, dis-
ability as measured by the Italian version of the
HAQ, the erythrocyte sedimentation rate (ESR)
measured using the Westergren method (mm/hour),
C-reactive protein (CRP) level, rheumatoid factor
(RF), the presence of morning stiffness, the use of
DMARDs and/or biological therapy (including de-
tails of the start and end of treatment and reasons
for treatment termination), concomitant therapies
with glucocorticosteroids or non-steroidal anti-in-
flammatory drugs (NSAIDs), and any adverse
events.
In addition to being evaluated individually, these
measures are also used to compute the DAS28 and
to define patient response to treatment on the ba-
sis of the EULAR criteria (7, 10, 11). The reasons
for discontinuing anti-TNF therapy are classified
into three major categories: adverse events, ineffi-
cacy (both primary lack of efficacy and secondary
loss of efficacy), and other reasons. In the case of
a switch from one TNF inhibitor to another, only
the first course is considered.
Follow-up
All of the patients are followed up for three years,
including those who stop therapy or switch to an-
other biological agent, using three approaches:
- Every six months, the attending rheumatologists
are asked to provide details of any changes in
therapy, current disease activity (DAS28) and,
specifically, the occurrence of any adverse event. 
- The patients are surveyed every six months (for
three years), and asked to complete a diary in-
cluding any new diagnoses, significant comor-
bidities and serious adverse events (defined as
any event leading to hospitalisation, whether or
not it is associated with therapy).
- All of the patients are flagged with the Italian
Office for National Statistics, whichnotifies the
registry of: any death (with a copy of the med-
ical information on the death certificate) and any
cancer.
Statistical analysis
The data used for this report were statistically
analysed using SPSS 15 for Windows software
(SPSS Inc., ILL, USA).
Results
The registry only records the data collected at
baseline, after six and 12 months, and then once
a year; so far, only the data relating to the first
36 months have been validated. For the purpos-
es of this study, we considered the 1010 patients
who had been followed up for at least six
months plus a further 54 who, although they had
been followed up for a shorter time, had already
discontinued anti-TNF therapy (intention-to-
treat approach) (Fig. 1).
The registry includes a total of 1114 patients: 533
(47.8%) treated with infliximab, 332 (29.8%) with
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adalimumab, and 249 (22.4%) with etanercept.
Table I shows their main demographic and clinical
characteristics at the start of anti-TNF treatment. In
brief, their mean age was 55.87 years and the mean
duration of RA was 7.78 years; 78.6% were posi-
tive for rheumatoid factor (RF). More than 38%
had comorbidities. 
The median number of previous DMARDs was
three per patient, the vast majority of whom had
previously received MTX. In combination with the
biological drug, 83.9% of the patients received
steroids (mean dose 4.92 mg/day), and 88.0% at
least one DMARD (83.8% methotrexate at a me-
dian dose of 12.35 mg/week). 
OTHER REGISTRIES OF BIOLOGICAL AGENTS
The introduction of new biological drugs for the
treatment of RA and other rheumatic diseases has
led to the implementation of specific registries in
various countries, all of which are designed to track
safety and efficacy. However, there are some dif-
ferences between them.
The German Registry Rheumatoid Arthritis Obser-
vation of Biologic Therapy (RABBIT) is an ongo-
ing, intensively monitored, observational cohort
study: the RA patients who start treatment with
any of the licensed biological agents are enrolled
in the case group, and the control subjects are those
monitored from the time they start a traditional
DMARD after the failure of at least one other
DMARD (12).
The British Society for Rheumatology (BSR) reg-
istry is a nationwide registry of patients with any
rheumatological disorder treated with biological
agents that is intended to assess the long-term tox-
icity and benefits of their use (13). However, one
specific characteristic of the BSR register is that it
also includes data from RA patients treated with
conventional DMARDs in order to be able to com-
pare the results (14).
The BIOBADASER registry, which was estab-
lished in February 2000 with the aim of actively
monitoring the long-term efficacy and safety of bi-
ological response modifiers in Spanish rheumatic
patients, includes about 60% of the total population
treated in Spain, and first defined the guidelines for
TB screening and treatment (15, 16).
The Swedish rheumatology register was the first to
organise registries for RA patients: ARTIS (An-
tirheumatic Therapies in Sweden), SSATG (South-
ern Sweden Anti-rheumatic Therapy Group), and
STURE (Stockholm Tumor Necrosis Factor Fol-
low-up Registry). These have demonstrated that
registries are not only extremely useful in evaluat-
ing the efficacy and safety of all of the drugs used
to treat RA, but also in conducting scientific re-
search studies of everyday practice (17).
The Consortium of Rheumatology Researchers of
North America (CORRONA) Registry collects
clinical practice data relating to patients with RA
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and psoriatic arthritis in order to evaluate their re-
sponses to biological agents (18).
Finally, the Czech National Registry has focused on
radiographic progression in patients treated with
anti-TNF agents, and reported that the improve-
ment in everyday practice is similar to that shown
by clinical trials (19).
CONCLUSIONS
The LORHEN registry data describe the effica-
cy and safety of the three currently available
TNF inhibitors during the first three years of
treatment in a large cohort of RA patients from
Lombardy, Italy.
SUMMARY
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages,
which consist of joint destruction. Clinical trials have shown that anti-tumour necrosis factor (TNF) drugs are effecti-
ve in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs). At about
the same time as the European approval of the third anti-TNF agent for treating rheumatoid arthritis (RA) patients, the
Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and
active follow-up of patients with RA treated with biological response modifiers. Since 1999, all patients with RA (ACR
criteria) and treated with at least one dose of an anti-TNF agent at four Rheumatology Centres in Lombardy (north-
west Italy) have been included in the Lombardy Rheumatology Network (LORHEN) registry in order to track the ef-
ficacy and safety of the three available TNF inhibitors during the first three years of treatment.
Key words - Lombardy Rheumatology Network (LORHEN) registry; rheumatoid arthritis; Italian Society of Rheu-
matology (Società Italiana di Reumatologia [SIR]).
Parole chiave - Registro Lombardy Rheumatology Network (LORHEN), artrite reumatoide, Società Italiana di Reu-
matologia (SIR).
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